Immuno Oncology Whitepaper Immuno Oncology Whitepaper

Therapies and Challenges

Explore the latest breakthroughs in this revolutionary field

Read our insightful whitepaper

by Shalini Tanwar | Team lead - In Vitro Biology (NBE-Oncology) at APSL

White Paper

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Author’s bio

Shalini Tanwar is an accomplished cellular immunologist specializing in cellular crosstalk during inflammation, autoimmunity, and immuno-oncology. With over 12 years of experience, she excels in designing and executing complex immune assays.

Shalini’s impressive achievements include validating experiments for immune cell redirection, expanding GD-T-cell populations by 300-fold, and uncovering the crosstalk between Treg cells and MDSCs. Currently serving as Team lead - In Vitro Biology (NBE-Oncology) at Aurigene, her expertise, and leadership in the field make her an invaluable asset in advancing research and development in the exciting and rapidly evolving field of immuno-oncology.

Download the whitepaper

About Aurigene

Aurigene Pharmaceutical Services Ltd. is a globally recognized contract research, development, and manufacturing organization (CDMO) that actively contributes to the advancement of pharmaceutical innovation. With a steadfast commitment to thought leadership, we offer comprehensive and integrated solutions to empower visionary companies in expediting their products from laboratory to market.    

At Aurigene, we seamlessly blend our extensive knowledge, experience, and cutting-edge technology to catalyze the progress of our clients' groundbreaking endeavours. Our unwavering dedication to innovation is underscored by our world-class research and development centres in India, boasting a team of over 650 exceptional scientists. These centres are fortified by state-of-the-art commercial manufacturing facilities strategically located in India, the United Kingdom, Mexico, and the United States.

Fueling biologics advancements    
with cutting-edge NBE services

Aurigene Pharmaceutical Services provides a wide range of high-quality and flexible scale development and manufacturing services for Biotherapeutics and Viral vectors. We are expanding our Biotherapeutics services, with a focus on mono-clonal antibodies(mAbs), therapeutic proteins and viral vectors. We are developing a facility which will meet the process development and clinical supplies needs of global biotech companies. The new facility is based on a state-of-the-art design concept, allowing maximum flexibility for a multi-product, multi-platform offering across proteins, mAbs, and viral vectors. We offer exclusive access to an established large-scale GMP manufacturing facility with a drug substance capacity of 15kl and fill-finish capabilities making it possible to provide commercial quantities seamlessly.

Fueling Biologics.jpg

Share your details to download our whitepaper

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

© 2023 Aurigene Pharmaceutical Services Ltd. | All rights reserved.


You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.